BRIEF—Linzess approved in Japan for constipation

Linzess, developed by Ironwood Pharmaceuticals (Nasdaq: IRWD) and licensed to Astellas in Japan, is sometimes marketed as Constella in international markets. It has been available in Japan since 2017 for use in irritable bowel syndrome with constipation.

The prevalence of constipation in Japan has been reported as 2.5% for men and 4.6% for women.